Nitin Patel

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

Jesús F. San Miguel, Binod Dhakal, Kwee Yong et al. · New England Journal of Medicine · 2023 · 733 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma

Simon J. Harrison, Tamia Nguyen, Marzia Rahman et al. · Blood · 2023 · 97 citations

Medicine, Hematology, Oncology +12

Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma

Sundar Jagannath, Thomas G. Martin, Yi Lin et al. · Journal of Clinical Oncology · 2025 · 83 citations · Full text

Medicine, Hematology, Oncology +17

CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma

Simon J. Harrison, Cyrille Touzeau, Nicolas Kint et al. · New England Journal of Medicine · 2025 · 51 citations

Life Sciences, Immunology, Oncology +17

First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma.

Binod Dhakal, Kwee Yong, Simon J. Harrison et al. · Journal of Clinical Oncology · 2023 · 31 citations

Pharmacy, Hematology, Pharmacotherapy +16